This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout

Data availability
The data supporting the findings of the study are available on request from the corresponding author (AS; asalhotra@coh.org). The data are not publicly available due to their containing information that could compromise the privacy of research participants
References
Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287–96. https://doi.org/10.1084/jem.188.2.287
Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106:2903–11. https://doi.org/10.1182/blood-2005-03-1257
Chinen T, Kannan AK, Levine AG, Fan X, Klein U, Zheng Y, et al. An essential role for the IL-2 receptor in T(reg) cell function. Nat Immunol. 2016;17:1322–33. https://doi.org/10.1038/ni.3540
Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5:179ra143 https://doi.org/10.1126/scitranslmed.3005265
Ito S, Bollard KM, Carlsten M, Malenhorst JJ, Biancotto A, Wang E, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther. 2014;22:1388–95. https://doi.org/10.1038/mt.2014.50
Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl J Med. 2011;365:2055–66. https://doi.org/10.1056/NEJMoa1108188
Foss FM, Gorgun G, Miller KB. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transpl. 2002;29:719–25. https://doi.org/10.1038/sj.bmt.1703529
Inamoto Y, Flowers MED, Sandmaier BM, Aki SZ, Carpenter PA, Lee SJ, et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood. 2014;124:1363–71. https://doi.org/10.1182/blood-2014-03-563544
Jagasia MH, Hildegard GT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21:389–401.e381. https://doi.org/10.1016/j.bbmt.2014.12.001
Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107:3074–80. https://doi.org/10.1182/blood-2005-09-3907
Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016;128:130–7. https://doi.org/10.1182/blood-2016-02-702852
Belizaire R, Kim HT, Poryanda SJ, Mircovic NV, Hipolito E, Savage WJ, et al. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019;3:969–79. https://doi.org/10.1182/bloodadvances.2018029124
Acknowledgements
IL-2 used in this trial was generously provided by Prometheus labs. Authors would like to thank City of Hope staff and nurses, as well as the patients and their families, without whom this work would not be possible. We would like to thank Ms. Golnaz Namdar (CRC) and Ms. Maridel Blandino (CRN) for their hard work.
Funding
This Phase 2 trial was funded by intramural Chairs Discretionary grant and NIH P30 CA033572 (Biostatistics and Genomics Core).
Author information
Authors and Affiliations
Contributions
AS and RN designed and conducted the study.SM helped write the paper. MT helped with statistical analysis. XW, WT and HQ performed the corelative studies. MAM, IA, BM, EK, ES and AP helped with patient care.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Salhotra, A., Talley, M., Wu, X. et al. Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease. Bone Marrow Transplant 57, 1045–1047 (2022). https://doi.org/10.1038/s41409-022-01671-0
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41409-022-01671-0
This article is cited by
-
Methotrexate/sirolimus/tacrolimus
Reactions Weekly (2023)